Christophe Reech, founder of the Reech Capital OTC derivatives valuation consultancy he founded in February 1999, is no longer at the company he sold to SunGard in June 2003.
Contrary to the London rumour mill, Reech says his departure was a natural conclusion to a two year integration period. “It was time for me to move on,” he says. “I have got a number of new things to work on, and I prefer to focus on them.” Reech adds that “Reech Capital is a very strong brand, and I do not think it would get any stronger if I was to stay on.”
For now, his new interests include “housekeeping” of various family interests, but Reech does also expect to resurface in the market in the autumn in “the field of expertise I have.” Which means derivatives, alternative investments and valuations, though not (he emphasises) in competition with SunGard.
Reech, who previously worked in the equity derivatives arms of BNP Paribas in Paris and Commerzbank in Frankfurt, set up Reech Capital after two years with Nikko Europe in London. Its best-known speciality, which sold well to hedge fund administrators, was model-based valuations of OTC derivatives.
Reech became president of the Reech operating unit of SunGard Trading and Risk Systems after the US technology company, which was recently taken private, acquired Reech Capital.